Guselkumab Response and Inhibition of Structural Damage Progression in Active Psoriatic Arthritis Across APEX Participant Subgroups

Philip J Mease,[1,2] Christopher T Ritchlin,[3] Laura C Coates,[4] Alexa P Kollmeier,[5] Bei Zhou,[6] Yusang Jiang,[6] Karen Bensley,[6] Koeun Im,[7] Rattandeep Batra,[8] Karissa Lozenski,[9] Soumya D Chakravarty,[9,10] Proton Rahman,[11] Désirée van der Heijde[12]
[1]Rheumatology Research, Providence Swedish Medical Center, Seattle, WA, USA; [2]University of Washington School of Medicine, Seattle, WA, USA; [3]Department of Medicine, Allergy/Immunology and Rheumatology, University of Rochester Medical Center, Rochester, NY, USA; [4]Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Botnar Research Centre, Oxford, UK; [5]Johnson & Johnson, LLC, San Diego, CA, USA; [6]Johnson & Johnson, LLC, Spring House, PA, USA; [7]Johnson & Johnson, LLC, Cambridge, MA, USA; [8]Johnson & Johnson, Inc., Toronto, Canada; [9]Johnson & Johnson, Horsham, PA, USA; [10]Drexel University College of Medicine, Philadelphia, PA, USA; [11]Craig L Dobbin Genetics Research Centre, Faculty of Medicine, Division of Rheumatology, Memorial University of Newfoundland, St. Johns, NL, Canada; [12]Leiden University Medical Center, Leiden, The Netherlands.

Key Takeaways

- **GUS-treated biologic-naïve pts with active and erosive PsA demonstrated significantly greater clinical improvement and significant inhibition of structural damage progression vs PBO at W24**
- **GUS effects were generally consistent across diverse subgroups of pts defined by baseline demographics, disease characteristics, medication use, and radiographic features of interest**
  - **Benefit in ACR20/50 clinical improvement was similar regardless of sex, BMI, PsA duration, joint involvement, CRP, and MTX use at baseline**
  - **Inhibition of radiographic progression observed across clinical and radiographic feature subgroups**

Background

Guselkumab (GUS), a fully-human monoclonal antibody able to bind to the CD64-receptor and simultaneously inhibit the interleukin (IL)-23p19 subunit, is indicated for moderate-to-severe plaque psoriasis, active psoriatic arthritis (PsA), and moderately-to-severely active Crohn's disease/ulcerative colitis

The ongoing phase 3b, randomized, double-blind, placebo (PBO)-controlled **APEX study (NCT04882098)** is further evaluating GUS effects on clinical and radiographic progression outcomes in **participants (pts) with active and erosive PsA**

APEX met primary (American College of Rheumatology ≥20% improvement [ACR20]) and major secondary (PsA-modified van der Heijde-Sharp [vdH-S] score change from baseline) endpoints, such that **GUS Q4W and Q8W demonstrated significantly higher rates of clinical improvement and significant inhibition of structural damage progression** vs PBO at Week(W)24

Objective

Evaluate consistency in GUS clinical response and radiographic progression inhibition across subgroups of pts of high clinical interest

APEX Study Design and Analysis Methods

Inclusion Criteria

- ✓ Biologic-naïve adults ≥18 years
- ✓ Active PsA ≥6 months (despite prior csDMARD, apremilast, NSAID); CASPAR criteria met
- ✓ ≥3 SJC; ≥3 TJC; CRP ≥0.3 mg/dL
- ✓ **≥2 erosive joints on radiographs of hands/feet**
- ✓ Active plaque psoriasis



Endpoints[a]	High Clinical Interest Baseline Subgroups[a]	Statistical Analysis
• Proportion achieving ACR20/50 response	**Demographics** (Sex, BMI) **PsA Characteristics** (Duration[c], SJC, TJC, CRP) **Medication Use** (MTX[c])	Pts who discontinued study intervention for any reason except natural disaster/major disruption, initiated/increased dose of non-biologic csDMARD or corticosteroid, or initiated prohibited therapies prior to W24 were coinsidered nonresponders[e]
• LSM change in PsA-modified vdH-S score		Based on an ANCOVA model[f]
• LSM change in PsA-modified vdH-S score	**Radiographic Features** (Total vdH-S, erosion, and JSN scores; joints with erosions/JSN)	Based on an ANCOVA model[f]

[a]Over 200 MI datasets. [b]29 subgroups were predefined to evaluate treatment consistency over baseline demographics (n=7), disease characteristics (n=12), medication use (n=5), and radiographic features (n=5); those of high clinical interest are reported here. [c]Predefined PsA duration subgroups categories were <1/≥1 to <3/≥3 years, however, <3/≥3 presented due to small sample size in <1 year category. [d]Predefined as csDMARD use at baseline, however, MTX component presented separately based on MTX representing the majority of csDMARD use at baseline. [e]Data impacted by, or missing due to, natural disaster/major disruption were imputed using MI; other missing data were imputed using NRI. [f]Explanatory model variables: baseline vdH-S score, treatment group, and randomization stratification level; data impacted by natural disaster/major disruption and missing data imputed using MI. ***ACR***=American College of Rheumatology, ***ANCOVA***=analysis of covariance, ***BMI***=body mass index, ***CASPAR***=Classification Criteria for Psoriatic Arthritis, ***CRP***=C-reactive protein, ***csDMARD***=conventional synthetic disease-modifying antirheumatic drug, ***F/U***=follow-up, ***GUS***=guselkumab, ***JSN***=joint space narrowing, ***LSM***=least squares mean, ***MI***=multiple imputation, ***MTX***=methotrexate, ***NRI***=nonresponder imputation, ***NSAID***=nonsteroidal anti-inflammatory drug, ***PBO***=placebo, ***PsA***=psoriatic arthritis, ***Q4W***=every 4 weeks, ***Q8W***=every 8 weeks, ***R***=randomization, ***SJC***=swollen joint count, ***TJC***=tender joint count, ***vdH-S***=van der Heijde-Sharp score, ***W***=week.

Results

Similar proportions of pts comprised baseline characteristic subgroups across treatment arms

- Pts with active and erosive PsA: median disease duration=5 years, SJC=9, TJC=16, and CRP=0.8 mg/dL

Modified full analysis set[a]	PBO (N=376)	GUS Q4W (N=273)	GUS Q8W (N=371)	Total (N=1020)
Sex				
Male	57%	55%	54%	55%
Female	43%	45%	46%	45%
BMI, kg/m²				
Normal <25	26%	24%	27%	26%
Overweight ≥25 to <30	37%	37%	37%	37%
Obese ≥30	37%	39%	37%	37%
PsA disease duration, yrs				
<3	32%	33%	32%	32%
≥3	68%	67%	68%	67%
SJC (0–66)				
<10	52%	56%	46%	51%
10 to 15	23%	23%	33%	27%
>15	24%	21%	21%	22%
TJC (0–68)				
<10	21%	21%	17%	19%
10 to 15	24%	27%	29%	27%
>15	55%	52%	54%	54%
CRP, mg/dL				
<1	59%	61%	57%	59%
1 to <2	19%	20%	24%	21%
≥2	22%	19%	19%	20%
MTX use at baseline				
Yes	60%	59%	60%	60%
No	40%	41%	40%	40%

[a]All randomized pts except those from Ukraine sites rendered unable to support key study operations due to major disruptions (N=1020). ***BMI***=body mass index, ***CRP***=C-reactive protein, ***GUS***=guselkumab, ***MTX***=methotrexate, ***PBO***=placebo, ***PsA***=psoriatic arthritis, ***pts***=participants, ***Q4W***=every 4 weeks, ***Q8W***=every 8 weeks. ***SJC***=swollen joint count, ***TJC***=tender joint count.

GUS treatment effect on joint disease activity was consistent across subgroups

- Aligned with primary endpoint results, GUS-treated pts had approximately 2-4 times higher odds of achieving ACR20 response than PBO-treated pts



ACR=American College of Rheumatology, ***BMI***=body mass index, ***CI***=confidence interval, ***CRP***=C-reactive protein, ***GUS***=guselkumab, ***MTX***=methotrexate, ***OR***=odds ratio, ***PBO***=placebo, ***PsA***=psoriatic arthritis, ***Q4W***=every 4 weeks, ***Q8W***=every 8 weeks, ***SJC***=swollen joint count, ***TJC***=tender joint count, ***W***=week.

GUS effect on the more stringent ACR50 response was also consistent across subgroups

- Aligned with overall ACR50 results, GUS-treated pts had approximately 2-6 times higher odds of achieving ACR50 response than PBO-treated pts

ACR=American College of Rheumatology, ***BMI***=body mass index, ***CI***=confidence interval, ***CRP***=C-reactive protein, ***GUS***=guselkumab, ***MTX***=methotrexate, ***OR***=odds ratio, ***PBO***=placebo, ***PsA***=psoriatic arthritis, ***Q4W***=every 4 weeks, ***Q8W***=every 8 weeks, ***SJC***=swollen joint count, ***TJC***=tender joint count, ***W***=week.

Significant inhibition of structural damage progression with GUS was generally consistent across baseline pt subgroups

- Concordant with known risk factors, PBO-treated pts with SJC >15 & CRP ≥2 mg/dL exhibited notably higher degrees of radiographic progression, leading to even more robust GUS effects in these groups



*Interaction p-value <0.05 for SJC GUS Q4W and Q8W;T; JC GUS Q8W; CRP GUS Q4W. ***BMI***=body mass index, ***CI***=confidence interval, ***CRP***=C-reactive protein, ***GUS***=guselkumab, ***LSM***=least squares mean, ***MTX***=methotrexate, ***PBO***=placebo, ***PsA***=psoriatic arthritis, ***Q4W***=every 4 weeks, ***Q8W***=every 8 weeks, ***SJC***=swollen joint count, ***TJC***=tender joint count, ***vdH-S***=van der Heijde-Sharp score, ***W***=week.

Baseline radiographic joint damage was of moderate degree and similar across treatment groups

	PBO (N=374)	GUS Q4W (N=271)	GUS Q8W (N=371)	Total (N=1016)
Baseline Radiographic Features				
Total vdH-S score [0-528]	11.5 [5.0–27.5]	11.0 [4.5–26.5]	11.0 [4.5–25.0]	11.0 [5.0–26.5]
Erosion score [0-320]	6.0 [2.5–13.0]	5.5 [2.5–13.0]	6.0 [2.5–14.0]	6.0 [2.5–13.5]
JSN score [0-208]	5.0 [1.5–14.0]	5.5 [1.5–14.9]	5.0 [1.0–14.5]	5.0 [1.5–14.5]

Values are median [interquartile range]. ***GUS***=guselkumab, ***JSN***=joint space narrowing, ***PBO***=placebo, ***Q4W***=every 4 weeks, ***Q8W***=every 8 weeks, ***vdH-S***=van der Heijde-Sharp score, ***W***=week.

Inhibition of structural damage progression with GUS was largely consistent regardless of baseline radiographic features

- PBO-treated pts with a vdH-S erosion score >6 and >4.5 erosive joints at baseline had the most radiographic progression at W24



*Interaction p-value <0.05 for erosion score GUS Q8W. ***CI***=confidence interval, ***GUS***=guselkumab, ***JSN***=joint space narrowing, ***LSM***=least squares mean, ***PBO***=placebo, ***Q4W***=every 4 weeks, ***Q8W***=every 8 weeks, ***vdH-S***=van der Heijde-Sharp score, ***W***=week.

PRESENTED BY: Hailey Soni at Florida Society of Rheumatology (FSR); July 16–19, 2025; Orlando, Florida USA. **REFERENCES: 1.** Mease PJ, et al. *Ann Rheum Dis*. 2025;84(12):1983–1994. **ACKNOWLEDGMENTS:** Medical writing support was provided by Kelly Koch, PharmD of Johnson & Johnson, under the direction of the authors in accordance with Good Publication Practice guidelines (*Ann Intern Med*. 2022;175:1298-1304). Layout design and reformatting for this encore presentation was provided by Sandeep Chavan of SIRO Medical Writing Pvt. Ltd, Thane, India (sponsored by Johnson & Johnson). This presentation was sponsored by Johnson & Johnson. **DISCLOSURES: PJM:** received grants from AbbVie, Acelyrin, Amgen, Bristol Myers Squibb, Eli Lilly, Johnson & Johnson, Novartis, and UCB; consulting fees from AbbVie, Acelyrin, Amgen, Bristol Myers Squibb, Century, Cullinan, Eli Lilly, Immagene, Johnson & Johnson, Novartis, Pfizer, Spyre, Takeda, and UCB; and speaker fees from AbbVie, Amgen, Eli Lilly, Johnson & Johnson, Novartis, Pfizer, and UCB. **CTR:** received grant/research support from Johnson & Johnson, Novartis, and UCB and consulting fees from AbbVie, Eli Lilly, Johnson & Johnson, Novartis, and UCB. **LCC:** has received grants/research support from AbbVie, Amgen, Celgene, Eli Lilly, Johnson & Johnson, Novartis, Pfizer and UCB; worked as a paid consultant for AbbVie, Amgen, Bristol Myers Squibb, Celgene, Eli Lilly, Gilead, Galapagos, Johnson & Johnson, Moonlake, Novartis, Pfizer, and UCB; and has been paid as a speaker for AbbVie, Amgen, Biogen, Celgene, Eli Lilly, Galapagos, Gilead, GlaxoSmithKline, Johnson & Johnson, Medac, Novartis, Pfizer, and UCB. **APK, BZ, YJ, KB, KI, RB, SDC,** and **HS (presenter):** are employees of Johnson & Johnson; employees may own stock/stock options in Johnson & Johnson. **KL:** is an employee of Johnson & Johnson and owns stock/stock options in Bristol Myers Squibb and Johnson & Johnson. **PR:** received consulting fees from AbbVie, Amgen, Bristol Myers Squibb, Celgene, Eli Lilly, Johnson & Johnson, Merck, Novartis, Pfizer, and UCB; meeting attendance/travel support from Johnson & Johnson; and research grants from Johnson & Johnson, and Novartis. **DvdH:** received consulting fees from AbbVie, Alfasigma, ArgenX, Bristol Myers Squibb, Eli Lilly, Grey-Wolf Therapeutics, Johnson & Johnson, Novartis, Pfizer, Takeda, UCB and is associate editor of Annals Rheumatic Diseases, and is an editorial board member Journal of Rheumatology, and director of Imaging Rheumatology BV.
PREVIOUSLY PRESENTED AT: Congress of Clinical Rheumatology – West (CCR-W); September 18–21, 2025; Huntington Beach, CA, USA.